Capital International Investors Has Raised Its Position in Ultragenyx Pharmaceutical INC (RARE) by $3.15 Million as Stock Declined

Investors sentiment decreased to 1.5 in Q2 2019. Its down 1.08, from 2.58 in 2019Q1. It turned negative, as 20 investors sold RARE shares while 36 reduced holdings. 23 funds opened positions while 61 raised stakes. 57.68 million shares or 0.70% more from 57.27 million shares in 2019Q1 were reported. Moreover, Ws Lllp has 0.09% invested in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). California Public Employees Retirement Systems holds 63,691 shares or 0% of its portfolio. Oppenheimer Asset Mngmt Inc reported 701 shares. Numerixs Investment Incorporated has 400 shares. California State Teachers Retirement Systems has 84,135 shares. Northern Corporation has invested 0.01% in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). Fincl Bank Of Montreal Can has 5,014 shares. Cap Investors stated it has 5.62 million shares or 0.14% of all its holdings. Metropolitan Life Insurance New York holds 0.02% or 16,653 shares in its portfolio. Proshare Advsrs Ltd accumulated 23,665 shares or 0.01% of the stock. Hood River Capital Management Ltd Liability, a Oregon-based fund reported 131,846 shares. Ww accumulated 1.87M shares. Rafferty Asset Mgmt Lc has invested 0.1% in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). Hudson Bay Capital Management Lp stated it has 110,000 shares or 0.16% of all its holdings. Moreover, Crestwood Advsr Group Inc Limited has 0.09% invested in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) for 32,708 shares.

Capital International Investors increased its stake in Ultragenyx Pharmaceutical Inc (RARE) by 0.9% based on its latest 2019Q2 regulatory filing with the SEC. Capital International Investors bought 50,013 shares as the company’s stock declined 6.08% . The institutional investor held 5.62 million shares of the major pharmaceuticals company at the end of 2019Q2, valued at $356.78 million, up from 5.57M at the end of the previous reported quarter. Capital International Investors who had been investing in Ultragenyx Pharmaceutical Inc for a number of months, seems to be bullish on the $2.54B market cap company. The stock decreased 1.32% or $0.59 during the last trading session, reaching $44.1. About 805,509 shares traded or 63.90% up from the average. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has declined 22.30% since September 13, 2018 and is downtrending. It has underperformed by 22.30% the S&P500.

Capital International Investors, which manages about $250.64 billion US Long portfolio, decreased its stake in Ryanair Holdings Plc Adr by 2.88M shares to 3.53M shares, valued at $226.72 million in 2019Q2, according to the filing. It also reduced its holding in Elanco Animal Health Inc by 789,745 shares in the quarter, leaving it with 1.50 million shares, and cut its stake in Church And Dwight Co Inc (NYSE:CHD).

More notable recent Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) news were published by: Nasdaq.com which released: “Hotelier bidding war may be Japanese wakeup call – Nasdaq” on September 02, 2019, also Nasdaq.com with their article: “One Very Worrying Chart Gives Echoes of 2001-2002 – Nasdaq” published on August 20, 2019, Marketwatch.com published: “Amazon stock a rare gainer after price target boosted to Street-high $2,600 – MarketWatch” on September 03, 2019. More interesting news about Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) were released by: Nasdaq.com and their article: “Alibaba set for ‘big challenge’ as flamboyant chairman Ma departs – Nasdaq” published on September 09, 2019 as well as Nasdaq.com‘s news article titled: “uniQure Announces Pricing of its Public Offering – Nasdaq” with publication date: September 06, 2019.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Ratings Coverage

Among 2 analysts covering Ultragenyx Pharmaceutical (NASDAQ:RARE), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Ultragenyx Pharmaceutical has $83 highest and $7500 lowest target. $77’s average target is 74.60% above currents $44.1 stock price. Ultragenyx Pharmaceutical had 5 analyst reports since March 15, 2019 according to SRatingsIntel. Morgan Stanley upgraded the stock to “Overweight” rating in Wednesday, March 27 report. As per Friday, August 2, the company rating was maintained by Morgan Stanley. Wedbush reinitiated the stock with “Outperform” rating in Friday, August 2 report.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.